Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma

International Journal of Oncology

Volumn 46, Issue 3, 2015, Pages 1039-1050

  Mataki, Hiroko ^a   Seki, Naohiko ^b   Chiyomaru, Takeshi ^a   Enokida, Hideki ^a   Goto, Yusuke ^b   Kumamoto, Tomohiro ^a   Machida, Kentaro ^a   Mizuno, Keiko ^a   Nakagawa, Masayuki ^a   Inoue, Hiromasa ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

EGFR; Lung squamous cell carcinoma; MET; MicroRNA; MiR 206; Receptor tyrosine kinase; Tumor suppressor

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MICRORNA 206; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; MET PROTEIN, HUMAN; MIRN206 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIGRATION INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL LUNG CARCINOMA; APOPTOSIS; CELL MOTION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84921908873     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2802     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D.: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Travis WD: Pathology of lung cancer. Clin Chest Med 32: 669-692, 2011.
3. Reck M, Heigener DF, Mok T, Soria JC and Rabe KF: Management of non-small-cell lung cancer: recent developments. Lancet 382: 709-719, 2013.
4. Gschwind A, Fischer OM and Ullrich A: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4: 361-370, 2004.
5. Cadena DL and Gill GN: Receptor tyrosine kinases. FASEB J 6: 2332-2337, 1992.
6. Engelman JA and Cantley LC: The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 12: S4372-S4376, 2006.
7. Gherardi E, Birchmeier W, Birchmeier C and Vande Woude G: Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12: 89-103, 2012.
8. Sacher AG, Janne PA and Oxnard GR: Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. Cancer 120: 2289-2298, 2014.
9. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007.
10. Bean J, Brennan C, Shih JY, et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104: 20932-20937, 2007.
11. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
12. Hobert O: Gene regulation by transcription factors andmicroRNAs. Science 319: 1785-1786, 2008.
13. Iorio MV and Croce CM: MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27: 5848-5856, 2009.
14. Rolfo C, Fanale D, Hong DS, et al: Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. Curr Pharm Biotechnol 15: 475-485, 2014.
15. Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114, 2008.
16. Friedman JM and Jones PA: MicroRNAs: critical mediators of differentiation, development and disease. Swiss Med Wkly. 139: 466-472, 2009.
17. Moriya Y, Nohata N, Kinoshita T, et al: Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J Hum Genet 57: 38-45, 2012.
18. Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2: 706-714, 2007.
19. Kojima S, Chiyomaru T, Kawakami K, et al: Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 106: 405-413, 2012.
20. Nohata N, Hanazawa T, Kinoshita T, et al: Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma. Br J Cancer 108: 1648-1658, 2013.
21. Kinoshita T, Nohata N, Hnasawa T, et al: Tumour-suppressive microRNA-29s inhibit cancer cell migration and invasion by targeting laminin-integrin signalling in head and neck squamous cell carcinoma. Br J Cancer 109: 2636-2645, 2013.
22. Yoshino H, Chiyomaru T, Enokida H, et al: The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer 104: 808-818, 2011.
23. Koeppen H, Yu W, Zha J, et al: Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib ± onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res 20: 4488-4498, 2014.
24. Itesako T, Seki N, Yoshino H, et al: The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster. PLoS One 9: e84311, 2014.
25. Hidaka H, Seki N, Yoshino H, et al: Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget 3: 44-57, 2012.
26. Nohata N, Hanazawa T, Enokida H and Seki N: microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget 3: 9-21, 2012.
27. Georgantas R, Streicher K, Greenless L, et al: MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D. Pigment Cell Melanoma Res 27: 275-286, 2014.
28. Missiaglia E, Shepherd C.J, Patel S, et al: MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas. Br J Cancer 102: 1769-1777, 2010.
29. Yan D, Dong Xda E, Chen X, et al: MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 284: 29596-29604, 2009.
30. Chen X, Yan Q, Li S, et al: Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERalpha-positive endometrioid adenocarcinoma. Cancer Lett 314: 41-53, 2012.
31. Kondo N, Toyama T, Sugiura H, et al: miR-206 expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 68: 5004-5008, 2008.
32. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.
33. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742, 2011.
34. Shaw AT, Yeap BY, Solomon BJ, et al: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12: 1004-1012, 2011.
35. Scagliotti GV, Novello S and von Pawel J: The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev 39: 793-801, 2013.
36. Gately K, Forde L, Cuffe S, et al: High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer. Clin Lung Cancer 15: 58-66, 2014.
37. Maroun CR and Rowlands T: The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther 142: 316-338, 2014.
38. Sadiq AA and Salgia R: MET as a possible target for non-small-cell lung cancer. J Clin Oncol 31: 1089-1096, 2013.
39. Cipriani NA, Abidoye OO, Vokes E and Salgia R: MET as a target for treatment of chest tumors. Lung Cancer 63: 169-179, 2009.
40. Nasser MW, Datta J, Nuovo G, et al: Down-regulation of micro-RNA-1 (miR-1)in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 283: 33394-33405, 2008.
41. Taulli R, Bersani F, Foglizzo V, et al: The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 119: 2366-2378, 2009.
42. Kefas B, Godlewski J, Comeau L, et al: microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68: 3566-3572, 2008.
43. Li Y, Vandenboom TG II, Wang Z, et al: miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 70: 1486-1495, 2010.
44. Acunzo M, Romano G, Palmieri D, et al: Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proc Natl Acad Sci USA 110: 8573-8578, 2013.